|
Institute of Medicine
35th Anniversary Annual Meeting
The National Academy of Sciences Building--2100 C Street, N.W.
Monday, October 24, 2005
Pharmaceuticals in the 21st Century
9:00 a.m.
Introduction of Program
Joseph P. Newhouse, Ph.D., John D. MacArthur Professor of Health Policy and Management, Harvard University
9:05 a.m.
The Drug Development Enterprise: 2005
Tadataka Yamada, M.D., Chairman, Research and Development, GlaxoSmithKline
9:25 a.m.
America's Third Transformation? Science-Based Innovation in the Past and Future
Louis Galambos, Ph.D., Professor of History, The Johns Hopkins University
9:35 a.m.
Gleevec: The Bellweather for Molecular Targeting
Brian J. Druker, M.D., Investigator, Howard Hughes Medical Institute and JELD-WEN Chair of Leukemia Research, Oregon Health & Science University Cancer Institute
9:55 a.m.
Drug Regulation for the 21st Century--Regulating for the Drugs We Need
Alastair J.J. Wood, M.D., Associate Dean and Professor of Medicine and Professor of Pharmacology, Vanderbilt University Medical Center
10:10 a.m.
Questions and Discussion
10:45 a.m.
The Evolving Nature of Academic-Industrial Alliances
Start-ups and Translational Funding
Mark G. Edwards, Managing Director, Recombinant Capital
The University Perspective
Lita L. Nelsen, M.S., Director, Technology Licensing Office, Massachusetts Institute of Technology
Opportunities and Challenges
Edward W. Holmes, M.D., Vice Chancellor for Health Sciences and Dean, School of Medicine, University of California, San Diego
11:15 a.m.
Questions and Discussion
11:25 a.m.
How Safe is Safe Enough? Drug Safety in the U.S. and the Developing World
Improving Drug Safety: A Systems Approach
Brian L. Strom, M.D., M.P.H., Professor and Chair, Department of Biostatistics and Epidemiology and Director, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine
The Experience of Rotavirus
Harry B. Greenberg, M.D., Senior Associate Dean for Research and Training, Stanford University School of Medicine
11:55 a.m.
Questions and Discussion
1:20 p.m.
Pricing, Promotion and Professional Interaction
Differential Pricing in the United States
Richard G. Frank, Ph.D., The Margaret T. Morris Professor of Health Economics, Department of Health Care Policy, Harvard Medical School
Differential Pricing--International and Ethical Implications
Patricia M. Danzon, Ph.D., Celia Moh Professor and Chair, Health Care Systems Department, The Wharton School, University of Pennsylvania
Patient's Perspective--Information and Access
Ellen L. Stovall, President and CEO, National Coalition for Cancer Survivorship
Professional Interactions
Jerry Avorn, M.D., Professor of Medicine, Harvard Medical School and Chief of the Division of Pharmaco-epidemiology and Pharmaco-economics, Brigham and Women's Hospital
Health Communications: Putting Patients and Doctors First
Karen Katen, Vice Chairman, Pfizer Inc. and President, Pfizer Human Health
2:10 p.m.
Questions and Discussion
2:25 p.m.
Intellectual Property
Incentives for Breakthrough Drugs
William B. Schultz, J.D., Partner, Zuckerman Spaeder LLP
Security Innovations in the 21st Century
Robert A. Armitage, Senior Vice President and General Counsel, Eli Lilly and Company
Improving Global Access While Preserving Incentives (cancelled)
Jean O. Lanjouw, Ph.D., Associate Professor, Department of Agricultural and Resource Economics, University of California, Berkeley
2:55 p.m.
Questions and Discussion
3:05 p.m.
Drugs for the Developing World
Introduction
Gail H. Cassell, Ph.D., Vice President, Scientific Affairs and Distinguished Lilly Research Scholar for Infectious Diseases, Eli Lilly and Company
Overview of Drug Development for Diseases of Poverty and the Role of the Private Sector
Trevor M. Jones, CBE, Ph.D., Former Director General, UK Pharmaceutical Association and Director, Allergan, Inc.--United Kingdom
Challenges of Access to Medicines in Africa--The Partnerships Needed
Pascoal Mocumbi, M.D., High Representative of the European and Developing Countries Clinical Trials Partnership, World Health Organization and Former Prime Minister of Mozambique
Note: Pascoal Mocumbi was not able to present his talk, however, Trevor Jones presented notes from Dr. Mocumbi's planned presentation.
Pharmaceuticals for the Developing World: The Role of the U.S. Government
Anthony S. Fauci, M.D., Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health
4:05 p.m.
Questions and Discussion
4:20 p.m.
Closing Remarks
Gail H. Cassell, Ph.D., Vice President, Scientific Affairs and Distinguished Lilly Research Scholar for Infectious Diseases, Eli Lilly and Company
4:25 p.m.
Presentation of the Gustav O. Lienhard Award
Harvey V. Fineberg, M.D., Ph.D., President, Institute of Medicine
and
Fitzhugh Mullan, M.D., Murdock Head Professor of Medicine and Health Policy, George Washington University School of Public Health and Health Services
Robert Brook, 2005 Recipient of Lienhard Award
4:45 p.m.
Introduction of the Class of 2004 IOM Members, 2005-2006 Robert Wood Johnson Health Policy Fellows and Senior Nurse Scholar-in-Residence
Harvey V. Fineberg, M.D., Ph.D.
Adjourn
Online presentations from the Annual Meeting are subject to copyright protection. Permission from the speaker is required prior to any copying, reproducing, or rebroadcasting any portion of the speaker's presentations. Additional copyright and legal policies of The National Academies can be read in the National Academies Legal Statement.
Program Planning Committee
Gail H. Cassell, Ph.D., Vice President, Scientific Affairs and Distinguished Lilly Research Scholar for Infectious Diseases, Eli Lilly and Company
Joseph P. Newhouse, Ph.D., John D. MacArthur Professor of Health Policy and Management, Harvard University
Susanne A. Stoiber, M.P.A., M.Sc., Executive Officer, Institute of Medicine
|